Table 1:
Characteristic of Study Subjects.
| Clinical Characteristics of Study Subjects (n = 16) | Mean ± SD | Frequency n (%) |
|---|---|---|
| Age (years) | 53.44 ± 10.92 | |
| Gender | ||
| Male | 11 (68.8) | |
| Female | 5 (31.3) | |
| Weight (kg) | 57.66 ± 10.54 | |
| Height (m) | 1.63 ± 0.09 | |
| BMI | 21.72 ± 3.70 | |
| Duration (months) | 9.44 ± 2.63 | |
| Treatment option | ||
| Chemotherapy | 13 (81.3) | |
| Tyrosine kinase inhibitor | 3 (18.8) | |
| COVID-19 history | ||
| Present | 3 (18.8) | |
| None | 13 (81.2) | |
| Cancer history | ||
| None | 16 (100) | |
| Stage | ||
| Stage IV | 16 (100) | |
| Comorbidities | ||
| Hypertension | 1 (6.3) | |
| Diabetes mellitus | 2 (12.5) | |
| Cardiac disease (CAD) | 1 (6.3) | |
| Cataract | 1 (6.3) | |
| None | 11 (68.8) |
Table 2:
Symptoms and Laboratory Parameters of Research Subjects.
| Parameters | Before therapy n (%) | After therapy n (%) | Before therapy (mean± SD) | After therapy (mean± SD) | P |
|---|---|---|---|---|---|
| Symptoms | |||||
| Cough | 3 (18.8) | 1 (6.3) | 0.625* | ||
| Hemoptysis | 4 (25.0) | 0 (0) | 0.125* | ||
| Shortness of breath | 10 (62.5) | 1 (6.3) | 0.004* | ||
| Chest pain | 2 (12.5) | 0 (0) | 0.500* | ||
| Metastasis symptoms | 6 (37.5) | 2 (12.5) | 0.125* | ||
| Laboratory | |||||
| Hemoglobin | 12.38 ± 2.02 | 11.52 ± 1.94 | 0.122** | ||
| Leucoytes | 10.90 ± 5.82 | 8.52 ± 4.88 | 0.034** | ||
| Platelets | 377.56 ± 151.36 | 359.50 ± 154.30 | 0.650*** |
Table 3:
miR-320b Parameter Before and After Therapy.
| miR-320b Before Therapy (mean ± SD) | miR-320b After Therapy (mean ± SD) | P*** |
|---|---|---|
| 1.00 ± 0.0 | 1.72 ± 2.40 | 0.856 |
Table 4:
Relationship between Treatment Response and miR-320b Levels After Therapy.
| miR-320b PR group (med (min – max)) | miR-320b SD group (med (min – max)) | miR-320b PD group (med (min – max)) | P**** |
|---|---|---|---|
| 0.72 (0.38 – 4.55) | 0.79 (0.14 – 9.70) | 1.29 (0.52 – 1.66) | 0.767 |
Table 5:
Relationship between miR-320b and Mortality.
| Mortality | miR-320b (med (min – max)) | P***** |
|---|---|---|
| Yes | 0,93 (0,14 – 2,76) | 0,791 |
| No | 0,85 (0,34 – 9,7) |
Table 6:
Relationship between Treatment Type and miR-320b Levels.
| Treatment | miR-320b (med (min – max)) | P***** |
|---|---|---|
| Chemotherapy | 0.93 (0.14 – 9.70) | 0.737 |
| TKI | 0.45 (0.38 – 4.55) |
Table 7:
Sensitivity and Specificity of miR-320b for Predicting Treatment Response.
| Positive for CR/PR if miR-320B is greater than or equal to | Sensitivity | 1 - Specificity |
|---|---|---|
| 0.240 | 1.000 | 0.900 |
| 0.360 | 1.000 | 0.800 |
| 0.400 | 0.833 | 0.800 |
| 0.435 | 0.667 | 0.800 |
| 0.485 | 0.500 | 0.800 |
| 0.620 | 0.500 | 0.700 |
| 0.785 | 0.500 | 0.600 |
| 0.890 | 0.500 | 0.500 |
| 0.960 | 0.500 | 0.400 |
| 1.195 | 0.333 | 0.400 |
| 1.525 | 0.167 | 0.400 |
| 1.655 | 0.167 | 0.300 |
| 2.210 | 0.167 | 0.200 |
| 3.655 | 0.167 | 0.100 |
Figure 1:
Overall Survival of Research Subject.
Figure 2:
Survival of Research Subjects undergoing Chemotherapy and Tyrosine Kinase Inhibitor Therapy.
Figure 3:
ROC Curve of the Relationship between miR-320b and Treatment Response.